Tonix Pharmaceuticals is committed to improving population health by inventing and developing innovative therapies and vaccines, through broad in-house capabilities and creative collaborations, to help address important unmet needs. Currently, our pipeline is primarily comprised of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Our infectious disease portfolio includes next-generation vaccines to prevent COVID-19 and a Smallpox and Monkeypox preventing vaccine. We are progressing small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions through our CNS portfolio. To learn more, visit www.tonixpharma.com